TrialHaematologica2016

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

David E Spaner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.